Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition: IDH1-mutant Cholangiocarcinoma Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Senior Adult Hepatobiliary Prehab Study
Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition: IDH1-mutant Cholangiocarcinoma Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Senior Adult Hepatobiliary Prehab Study
Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition: IDH1-mutant Cholangiocarcinoma Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Senior Adult Hepatobiliary Prehab Study
Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Condition: IDH1-mutant Cholangiocarcinoma Interventions: Drug: Ivosidenib; Drug: Recommended Combination Dose (RCD) of ivosidenib; Drug: Nivolumab; Drug: Ipilimumab Sponsors: Servier Bio-Innovation LLC; Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Senior Adult Hepatobiliary Prehab Study
Conditions: Hepatobiliary Cancer; Cholangiocarcinoma; Liver Metastases Interventions: Behavioral: Resistance Training; Behavioral: Aerobic Training Sponsor: H. Lee Moffitt Cancer Center and Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 27, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
